HB695 (2019) Detail

Relative to transparency of nonprofit patient advocacy organizations.


HB 695 - AS AMENDED BY THE HOUSE

 

19Mar2019... 0761h

2019 SESSION

19-0735

01/04

 

HOUSE BILL 695

 

AN ACT relative to transparency of nonprofit patient advocacy organizations.

 

SPONSORS: Rep. McBeath, Rock. 26

 

COMMITTEE: Commerce and Consumer Affairs

 

-----------------------------------------------------------------

 

AMENDED ANALYSIS

 

This bill requires nonprofit organizations advocating on behalf of patients or that fund medical research to compile a report relative to payments received from certain manufacturers, insurance carriers, or pharmacy benefit managers.  The nonprofit organization shall post the report on its Internet website or file it with the insurance commissioner.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

19Mar2019... 0761h 19-0735

01/04

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Nineteen

 

AN ACT relative to transparency of nonprofit patient advocacy organizations.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

1  New Section; Transparency of Nonprofit Patient Advocacy Organizations.  Amend RSA 400-A by inserting after section 30 the following new section:

400-A:30-a  Transparency of Nonprofit Patient Advocacy Organizations.  

I.  In this section, “patient advocacy organization” means any formally organized nonprofit group that primarily concerns itself with medical conditions or potential medical conditions and has a mission and takes actions that seek to help people affected by those medical conditions or to help their families.  “Patient advocacy organization” shall not include a professional organization typically focusing on advancing its profession or serving professional members as a primary goal.

II.(a)  On or before January 1 of each year, any patient advocacy organization that has received a payment, donation, subsidy or anything else of value from a pharmaceutical manufacturer, health insurance carrier, or pharmacy benefit manager, or a trade or advocacy group for pharmaceutical manufacturers, health insurance carriers, or pharmacy benefit managers during the immediately preceding calendar year shall compile a report which includes:

(1)  For each such contribution, the amount of the contribution and the pharmaceutical manufacturer, affiliated third party, pharmacy benefit manager, or group that provided the payment, donation, subsidy or other contribution; and

(2)  The percentage of the total gross income of the organization during the immediately preceding calendar year attributable to payments, donations, subsidies, or other contributions from each pharmaceutical manufacturer, health insurance carrier, pharmacy benefit manager, or group.

(b)  Except as otherwise provided in this section, the patient advocacy organization shall post the report on its Internet website which is accessible by the public.  If the nonprofit organization does not maintain an Internet website that is accessible to the public, the nonprofit organization shall submit the report compiled pursuant to subparagraph (a) to the insurance department.

III.  Any patient advocacy organization that has received a payment, donation, subsidy or anything else of value from a pharmaceutical manufacturer, health insurance carrier, or pharmacy benefit manager, or a trade or advocacy group for pharmaceutical manufacturers, health insurance carriers, or pharmacy benefit managers during the immediately preceding calendar year shall disclose that fact when testifying, lobbying, or otherwise engaging in person with a member of the general court.

IV.  Any patient advocacy organization that has a paid employee of the organization who is a registered lobbyist with the state of New Hampshire and is wearing a name tag in compliance with RSA 15:2 or otherwise identifies him or herself as a lobbyist shall be exempt from this section.

V.  Any patient advocacy organization found in violation of this section may be fined up to $1,000 per violation.

2  Effective Date.  This act shall take effect upon its passage.

Links


Date Body Type
March 5, 2019 House Hearing
March 8, 2019 House Exec Session
March 8, 2019 House Exec Session
House Floor Vote
March 19, 2019 House Floor Vote
April 25, 2019 Senate Hearing
April 30, 2019 Senate Hearing
May 7, 2019 Senate Hearing
Senate Floor Vote
May 30, 2019 Senate Floor Vote

Bill Text Revisions

HB695 Revision: 5600 Date: March 19, 2019, 5:03 p.m.
HB695 Revision: 4986 Date: Jan. 17, 2019, 2:38 p.m.

Docket


May 30, 2019: Inexpedient to Legislate, MA, VV === BILL KILLED ===; 05/30/2019; SJ 18


: Committee Report: Inexpedient to Legislate


May 30, 2019: Committee Report: Inexpedient to Legislate, 05/30/2019; SC 24


May 7, 2019: ==RECONVENE== Hearing: 05/07/2019, Room 100, SH, 01:00 pm; SC 21


April 30, 2019: ==RECESSED== Hearing: 04/30/2019, Room 102, LOB, 02:45 pm; SC 20


April 25, 2019: ==RECESSED== Hearing: 04/25/2019, Room 100, SH, 01:00 pm; SC 19


March 28, 2019: Introduced 03/28/2019 and Referred to Commerce; SJ 12


March 19, 2019: Ought to Pass with Amendment 2019-0761h: MA VV 03/19/2019 HJ 10 P. 16


March 19, 2019: Amendment # 2019-0761h: AA VV 03/19/2019 HJ 10 P. 16


March 19, 2019: Committee Report: Ought to Pass with Amendment # 2019-0761h for 03/19/2019 (Vote 18-2; CC) HC 16 P. 6


: Committee Report: Ought to Pass with Amendment # 2019-0761h (Vote 18-2; CC)


March 8, 2019: Executive Session: 03/08/2019 01:30 pm LOB 302-304


March 8, 2019: Subcommittee Work Session: 03/08/2019 09:00 am LOB 302-304


March 6, 2019: Subcommittee Work Session: 03/06/2019 08:30 am LOB 302


March 5, 2019: Public Hearing: 03/05/2019 10:30 am LOB 302


Jan. 3, 2019: Introduced 01/03/2019 and referred to Commerce and Consumer Affairs HJ 3 P. 26